Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04992559 | A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC | recruiting | Phase 2 | 41 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05806073 | Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma | not yet recruiting | N/A | 188 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER |
| 0 |
| Apr 12, 2023 |
| clinicaltrials |
| NCT05740995 | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | recruiting | — | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05778253 | The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05775419 | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC | recruiting | N/A | 1,216 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05759325 | An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma | not yet recruiting | — | 100 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Mar 8, 2023 | clinicaltrials |
| NCT05732662 | SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC | not yet recruiting | Phase 2 | 25 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05693116 | Survival and Prognostic Factors of Squamous Cell Carcinoma of the Nasal Vestibule(NV-SCC) | recruiting | — | 300 | Istituto Clinico HumanitasOTHER | 3 | Jan 20, 2023 | clinicaltrials |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | active not recruiting | Phase 3 | 1,590 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05252078 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients(ALTER-E005) | recruiting | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05611515 | Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies(SUPRA-QoL) | recruiting | — | 108 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | not yet recruiting | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04681469 | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC(PRIME) | recruiting | Phase 2 | 49 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05459415 | Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC | active not recruiting | N/A | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05420480 | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy | not yet recruiting | N/A | 323 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04519905 | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | recruiting | N/A | 320 | Fudan UniversityOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04976478 | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | not yet recruiting | — | 125 | Peking University Third HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04522687 | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | recruiting | — | 500 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02990936 | Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy(TGV-PI) | not yet recruiting | — | 120 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01688908 | Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)(ESECC) | active not recruiting | N/A | 33,948 | Peking UniversityOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02490735 | CIK in Treating Patients With Esophageal Cancer | not yet recruiting | Phase 2 | 2,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 7, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Apr 14, 2023source: clinicaltrials